SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...

VIJAYAWADA: State secretary of the Communist Party of India (CPI), Gujjula Eswarayya, on Monday shot off a strongly worded ...

AbbVie secures Canadian support for Skyrizi in ulcerative colitis with new reimbursement recommendations and a completed pCPA agreement.

The Department of Transportation has announced it will roll back widely lauded Biden-era plans to reimburse travelers for ...

Hopewell announced late in October that it would begin phasing out reimbursements to city retirees not on the city-backed insurace plans.

AbbVie (ABBV) has announced two updates for Canadians living with ulcerative colitis. Canada’s Drug Agency has recommended ...

Its involvement often leads to distortions and perverse incentives.

The state’s appeals process historically overturns close to 40% of denials, offering an impartial medical review.

Holding that a Letter of Interest (LoI) does not confer any enforceable or vested rights until all stipulated pre-conditions ...

The State Attorney General has issued a cease-and-desist letter to OptumRx concerning reports that the pharmacy benefit manager attempted to engage in illegal, retroactive reimbursement clawbacks ...

Hugh Futrell’s recent Close to Home article was a free financial consultation for Santa Rosa City Schools ( “Santa Rosa ...